



## **Imaxio sells Trolovol® (D-penicillamine) to focus on vaccines**

**This divestment enables Imaxio to focus exclusively  
on the development of its pipeline of vaccine candidates  
based on the IMX313 technology,  
and on the commercialisation of the vaccine Spirolept®**

**Lyon, France – December 1<sup>st</sup> 2016** – Imaxio, a biotech company specializing in immunology announces today the sale of Trolovol® (D-penicillamine), a drug for human usage indicated for an orphan disease affecting around 1,200 patients in France. The transaction was facilitated by CMC Consulting Group.

This sale is aligned with Imaxio's willingness to refocus its business on vaccines. This is the result of several years of work by Imaxio's teams, which have increased Trolovol®'s turnover since its acquisition by Imaxio in May 2012. Thanks to this deal, Imaxio will now focus on the commercialization of Spirolept®, its human vaccine indicated for the prevention of a professional infectious disease, and on the development of its vaccines pipeline, based on its proprietary technology IMX313.

IMX313 is an antigen re-engineering pro-immunogenic technology which significantly improves the efficacy of vaccines with which it is used. Thanks to IMX313, Imaxio is currently developing a clinical-stage pipeline composed of several vaccine candidates indicated to prevent or treat malaria (phase I), influenza (preclinical phase), and some types of cancer (research).

Spirolept®, which is marketed in France, generates more than EUR 2 million sales. Imaxio is currently evaluating the opportunity to export the product in a European country and several emerging countries. Imaxio remains open to acquisitions or collaborations to distribute other vaccines than Spirolept® in France.

"We are delighted to have finalized this transaction, which highlights the efficacy with which Imaxio's teams have managed Trolovol® since 2012," said Alexandre Le Vert, Chief Executive Officer of Imaxio. "This sale will enable our teams to focus exclusively on vaccines, and to work synergistically for the development of our clinical-stage vaccine pipeline based on IMX313 technology."

### **About Imaxio SA**

Imaxio is a small biotechnology company focused on immunology, with products ranging from commercial stage to clinical and preclinical R&D stages.

Imaxio commercializes in France a human vaccine indicated for the prevention of an infectious occupational disease, called Spirolept®.

Its clinical-stage R&D pipeline is focused on vaccines for infectious diseases (malaria, influenza, etc.) and an immunotherapy in oncology.

It is based on the IMX313 technology, an antigen re-engineering platform developed by Imaxio to improve the efficacy of vaccines, which is protected by a strong portfolio of 4 patent families.

Imaxio partners with national and international renowned research structures, including the Jenner Institute at Oxford University (UK), the German Cancer Research Centre (DKFZ), Inserm (France), CNRS (France) and the Léon Bérard Cancer Centre (Lyon, France).

Based in Lyon (France), more than half of the twenty Imaxio employees is dedicated to R&D activities. In 2015, its turnover reached EUR 2 million.

For further information: [www.imaxio.com](http://www.imaxio.com)

### **About CMC Consulting Group**

The CMC Group is an international advisory firm providing integrated transaction services, management and medical affairs consulting to companies in the life science industries. This integration provides clients a seamless interface between strategy and implementation and incorporates a range of perspectives designed to optimize engagement outcomes. With offices in the United States, Asia and throughout the EU, the firm complements global industry knowledge with rich local market insight.

For further information: <http://www.cmc-co.net>

---

**For further information, please contact:**

Imaxio SA  
Raphaël METROP  
[rmetrop@imaxio.com](mailto:rmetrop@imaxio.com)

---